Trajenta

Trajenta (Linagliptin) is a dipeptidyl peptidase 4 inhibitor (DPP-4) prescribed to treat type 2 diabetes that operates by increasing incretin levels and the amount of insulin released in the body while decreasing the amount of sugar produced by the body. When prescribed along with a balanced diet and exercise the medication can be used to control high blood sugar levels in the body. This can reduce symptoms of high blood sugar such as nerve problems, blindness, kidney damage, and even reduce risk of limb loss, heart attacks, or strokes.

Trajenta (Linagliptin) is typically taken orally once a day at a dosage of one tablet, but your particular instructions will depend on your health condition and the severity of your symptoms. These should be swallowed with a large glass of water and may be taken on an empty stomach, although a meal or snack is recommended before use if you experience nausea. Do not change the form of the tablets before use to avoid destroying or altering the effects of their contents.

Even though Trajenta (Linagliptin) will not cause side effects in most people, some patients may experience unusual symptoms such as:

• Nausea or vomiting
• Headache
• Cough
• Runny or stuffy nose
• Back pain
• Muscle or joint pain
• Loss of appetite

Call your physician immediately should symptoms persist or if you encounter more severe side effects such as:

• Pancreatitis
• Irregular heartbeat
• Blurred vision
• Tingling in hands or feet
• Swelling of the face, tongue, throat or lips

Trajenta (Linagliptin) should not be used by patients who are pregnant, breastfeeding, or who have type 1 diabetes, or diabetic ketoacidosis.